Study objectives We report on the long-term safety and efficacy of bosentan treatment in
patients with pulmonary arterial hypertension (PAH). Background In a preceding study …

Objective Pulmonary arterial hypertension (PAH) is a condition which may lead to right
ventricular failure and premature death. While recent data supports the initial combination of …

Background—Pulmonary arterial hypertension (PAH) is a progressive, fatal disease with no
cure. Parenteral and inhaled prostacyclin analogue therapies are effective for the treatment …

BACKGROUND: Monotherapy and sequential combination therapy have been widely used
in the treatment of pulmonary arterial hypertension (PAH). There is limited evidence for initial …

Two studies with both clinical and societal significance are published in this Journal of Heart
and Lung Transplantation focus issue on pulmonary hypertension. The Treprostinil for …

Study objective Pulmonary arterial hypertension (PAH) is a progressive disease with a bad
prognosis. Prostanoids are well established in the medical treatment of this disease …

PURPOSE: PAH related to CTD is progressive and difficult to manage. The multicenter,
randomized, placebo (PBO) controlled bosentan BREATHE-1 PAH trial reported a trend …

Aim: To evaluate effects of chronically administered inhaled treprostinil (TRE), a prostacyclin
analogue, in patients with PAH. Methods: Evaluation of inhaled TRE (up to 72 µg four times …

Pulmonary vascular diseases such as pulmonary embolism and pulmonary hypertension
are important and frequently under-recognised conditions. This article provides an overview …

PURPOSE: To determine the effects of chronically administered oral treprostinil
diethanolamine (TRE), a prostacyclin analogue formulated as a sustained release tablet, on …